EnteroMedics Inc  

(Public, NASDAQ:ETRM)   Watch this stock  
Find more results for ETRM
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.85 - 2.17
Open     -
Vol / Avg. 0.00/347,954.00
Mkt cap 82.59M
P/E     -
Div/yield     -
EPS -0.38
Shares 74.40M
Beta 2.13
Inst. own 26%
Aug 5, 2015
Q2 2015 EnteroMedics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 30, 2015
Q1 2015 EnteroMedics Inc Earnings Release
Mar 10, 2015
EnteroMedics Inc at ROTH Conference
Mar 4, 2015
EnteroMedics Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -200.37% -128.17%
Return on average equity -411.68% -244.84%
Employees 28 -
CDP Score - -


2800 Patton Rd
SAINT PAUL, MN 55113-1100
United States - Map
+1-302-6587581 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company’s initial product is the Maestro System that has been developed in two different energy configurations, the Maestro Radio Frequency (RF) System and the Maestro RC System, delivering the same VBLOC therapy. The Maestro RF System is powered by an external controller and transmit coil worn by the patient to receive therapy. The Maestro RC System is powered by an internal rechargeable battery. The components of the Maestro RC System include neuroregulator, lead system, mobile charger, transmit coil and clinician programmer.

Officers and directors

Mark B. Knudson Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Gregory S. Lea Chief Financial Officer, Chief Operating Officer
Age: 62
Bio & Compensation  - Reuters
Adrianus Donders Senior Vice President - Research and Advanced Development
Age: 61
Bio & Compensation  - Reuters
Tonya Dowd Vice President - Reimbursement
Bio & Compensation  - Reuters
Katherine S. Tweden Ph.D. Vice President - Clinical and Regulatory
Age: 54
Bio & Compensation  - Reuters
Brad Hancock Chief Commercial Officer
Bio & Compensation  - Reuters
Anthony P. Jansz Director
Age: 54
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Age: 54
Bio & Compensation  - Reuters
Carl S. Goldfischer M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Bobby I. Griffin Independent Director
Age: 77
Bio & Compensation  - Reuters